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Early detection is imperative for improving survival from ovarian cancer, the leading cause
of death from gynecological cancer in the United States. At the Health and Medicine for
Women continuing medical education (CME†) conference at Yale in September 2010, Dr.
Gil Mor, a researcher in the Department of oB/GYN at Yale, presented recent advances on
the pathophysiology of ovarian cancer. These advances, and particularly our growing un-
derstanding of cancer stem cells, may help overcome the limitations of current ovarian can-
cer detection and treatment methods.
Ovarian cancer is the leading cause of
death due to gynecological cancer in the
United States, with an estimated 21,880
new cases and 13,850 deaths predicted in
2010 [1]. The disease often presents with
such vague symptoms such as abdominal
discomfort, difficulty eating, and feeling
full quickly. For this reason, it is called “the
disease  that  whispers.”  Since  adequate
screening methodologies are lacking, most
women first present with either stage III or
IV disease. Stage I disease is associated
with a 90 percent cure rate, making early
detection methods imperative [2]. 
There are several reasons for the lack
of an effective means of screening for ovar-
ian cancer. First, in order for a cancer to be
adequately detected, it must produce a de-
tectable biomarker. This substance should
be present in higher quantities in afflicted
patients and also must be specific enough
for the particular malignancy. To date, the
only ovarian cancer-associated biomarker
is CA-125. However, estrogen and other
hormones can affect the levels of CA-125,
leading to many false positives and pre-
cluding the widespread use of this bio-
marker in women with no previous history
of cancer [3]. Other proteins are also ele-
vated  in  ovarian  cancer,  but  none  has
proven specific and sensitive enough for
cancer screening. 
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the “rules” of malignancy. Generally, when
a neoplasm first develops, a single mono-
clonal cell accumulates enough mutations
that allow it to escape the normal check-
points for apoptosis and mitosis [4]. This
cell produces clonal progeny of the same
genotype. Each clone has the possibility to
undergo environmentally induced and en-
dogenous mutations that allow the neoplasm
to expand and grow [5]. However, in the
1990s, a group of researchers discovered a
malignant cell derived from acute myeloid
leukemia that was able to recapitulate the
original disease after transplantation into
mice [6]. This cell type had the surprising
potential to both self-renew and produce a
new lineage of cells within a malignancy.
Dubbed “cancer stem cells,” even solid ma-
lignancies ranging from prostate to liver
cancer have been found to contain them.
One of the hallmark features of these cells
is that they do not uniformly produce bio-
markers that can be used for broad screen-
ing, further limiting ovarian cancer detection
methods. 
Cancer stem cells are thought to cause
recurrence after surgery and chemotherapy.
In fact, while 80 percent of ovarian cancer
cases respond to initial chemotherapy, less
than  15  percent  remain  in  remission  [7].
Most chemotherapeutic agents target rapidly
dividing cells, but since cancer stem cells di-
vide slowly, they are not fully killed by these
drugs. Dr. Gil Mor, a researcher in the De-
partment of OB/GYN at Yale, studies which
molecular components enable ovarian can-
cer stem cells to bypass treatment and con-
tinue to differentiate. He has discovered a
distinct genetic profile that allows them to
proliferate despite chemotherapy and pro-
mote  recurrence  of  the  neoplasm.  More
specifically, ovarian cancer stem cells pre-
senting the surface antigen CD44 are char-
acterized by constitutive NFʺB signaling [8].
Since NFʺB has been implicated in cytokine
production and inflammation, its constitutive
activity could result in a high capacity for
cellular repair and proliferation [9].
Dr. Mor and colleagues also have dis-
covered that cancer stem cells have the abil-
ity to promote tumor vascularization. Mice
injected with CD44+ ovarian cancer stem
cells exhibited highly vascularized tumors.
When these cells were placed in an in vitro,
three-dimensional matrigel matrix, which is
often used to study endothelial differentia-
tion, they generated vessel-like structures
within 24 hours. In contrast, mature, non-
stem ovarian cancer cells did not demon-
strate significant vessel growth [10]. The
same paper also established that cancer stem
cell-derived vascular progenitor cells could
differentiate into endothelial cells of human
origin. The cells grew independently of vas-
cular endothelial growth factor (VEGF), re-
lying  instead  on  IKKʲ,  an  enzyme  that
activates NFʺB [10].
In another study, Szotek and colleagues
injected stem cells from genetically engi-
neered mouse ovarian cancer cells (MOV-
CAR 7 cell line) into the dorsal fat pad of
nude mice. Tumors appeared in 3/3 animals
at 10 weeks, as compared to no detectable
tumors in 0/3 animals injected with non-
stem ovarian cancer cells at 10 weeks [11].
However, at 14 weeks, 2/3 mice injected
with non-stem cells had detectable tumors.
Flow cytometry analysis revealed that the
cancer stem cells were less homogenous
than the non-cancer stem cell population,
suggesting that the former have the poten-
tial to initiate tumor growth earlier and with
lower numbers. 
Another group studied the presence of
mitochondrial mutations in ovarian cancer
cells. They discovered three nucleotide vari-
ations that were highly expressed in the cod-
ing  regions  of  epithelial  ovarian  cells,
potentially qualifying as an ovarian stem cell
marker [12]. Further analysis revealed that
these  mitochondrial  variations  were  not
found in ovarian cancer stem cell clones. Yet
germline mutations were found in these can-
cer stem cell clones, suggesting that the ge-
netic  profiling  of  these  tumors  could  be
error-prone. These findings underscore the
difficulties in attempting to find a suitable
marker for ovarian cancer.  
Although detecting ovarian cancer will
likely remain challenging for some time, re-
searchers are much closer to discovering the
48 Ahmad: Advances in ovarian cancer screeningreasons for its recurrence and resistance to
conventional therapy. With the advancement
of research on cancer stem cells, women di-
agnosed with ovarian cancer in the future
hopefully will have a better prognosis than
current patients.
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